HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use DARIFENACIN EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for DARIFENACIN **EXTENDED-RELEASE TABLETS.** DARIFENACIN extended-release tablets, for oral use Initial U.S. Approval: 2004 RECENT MAJOR CHANGES ... Warnings and Precautions: Central Nervous System Effects (5.5) 03/2012 INDICATIONS AND USAGE Darifenacin extended-release tablets are muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. (1) (1) DOSAGE AND ADMINISTRATION The recommended starting dose of darifenacin extended-release tablets is 7.5 mg once daily. Based upon individual response, the dose may be increased to 15 mg once daily, as early as two weeks after starting therapy. (2) (2) The daily dose of darifenacin extended-release tablets should not exceed 7.5 mg in the following patients: (2) • Patients with moderate hepatic impairment (Child-Pugh B) (2, 8.6) Patients taking potent CYP3A4 inhibitors (2, 7.1) Darifenacin extended-release tablets are not recommended for use in patients with severe hepatic impairment (Child-Pugh C). (2, 8.6) (2) Darifenacin extended-release tablets may be taken with or without food. The tablet should be swallowed whole with water and not chewed, divided or crushed. (2) (2) DOSAGE FORMS AND STRENGTHS Extended-release tablets 7.5 mg and 15 mg. (3) (3) CONTRAINDICATIONS Darifenacin extended-release tablets are contraindicated in patients with, or at risk for, the following conditions (4): (4) • urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. ------ WARNINGS AND PRECAUTIONS • Darifenacin should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention. (5.1) Dariferacin should be administered with caution to patients with gastrointestinal obstructive disorders because of the risk of gastric retention. (5.2) · Darifenacin should be used with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks. (5.3) Central Nervous System Effects: Somnolence has been reported with darifenacin . Advise patients not to drive or operate heavy machinery until they know how darifenacin affect them. (5.5) ADVERSE REACTIONS The most frequently reported adverse reactions (>3 percent) for darifenacin extended-release tablets are: constipation, dry mouth, headache, dyspepsia, nausea, urinary tract infection, accidental injury, and flu symptoms. (6) (6) To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. (6)

 Caution should be taken when darifenacin is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants. (7.2)

 The concomitant use of darifenacin with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to effects of gastrointestinal motility. (7.3)

USE IN SPECIFIC POPULATIONS

- Pregnancy: Darifenacin should be used during pregnancy only if the benefit to the mother outweighs the potential risk to the fetus. (8.1)
- Nursing Mothers: It is not known whether darifenacin is excreted into human milk and therefore caution
- should be exercised before darifenacin are administered to a nursing woman. (8.3)
- Pediatric Use: The safety and effectiveness of darifenacin in pediatric patients have not been established. (8.4)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 1/2023

FULL PRESCRIBING INFORMATION: CONTENTS*

- 1 INDICATIONS AND USAGE
- 2 DOSAGE AND ADMINISTRATION
- **3 DOSAGE FORMS AND STRENGTHS**

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Risk of Urinary Retention
- 5.2 Decreased Gastrointestinal Motility
- 5.3 Controlled Narrow-Angle Glaucoma
- 5.4 Angioedema
- 5.5 Central Nervous System Effects

5.6 Patients with Hepatic Impairment

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Post Marketing Experience

7 DRUG INTERACTIONS

- 7.1 CYP3A4 Inhibitors
- 7.2 CYP2D6 Inhibitors
- 7.3 CYP2D6 Substrates
- 7.4 CYP3A4 Substrates
- 7.5 Combination oral contraceptives
- 7.6 Warfarin
- 7.7 Digoxin

7.8 Other Anticholinergic Agents

- 8 USE IN SPECIFIC POPULATIONS
 - 8.1 Pregnancy
 - 8.3 Nursing Mothers
 - 8.4 Pediatric Use
 - 8.5 Geriatric Use
 - 8.6 Hepatic Impairment
 - 8.7 Renal Impairment
- 8.8 Gender

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Darifenacin is muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

2 DOSAGE AND ADMINISTRATION

The recommended starting dose of darifenacin extended-release tablets is 7.5 mg once daily. Based upon individual response, the dose may be increased to 15 mg once daily, as early as two weeks after starting therapy.

Darifenacin extended-release tablets should be taken once daily with water. Darifenacin extended-release tablets may be taken with or without food, and should be swallowed whole and not chewed, divided or crushed.

For patients with moderate hepatic impairment (Child-Pugh B) or when co-administered with potent CYP3A4 inhibitors (for example, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone), the daily dose of darifenacin extended-release tablets should not exceed 7.5 mg. Darifenacin is not recommended for use in patients with severe hepatic impairment (Child-Pugh C) [see Warnings & Precautions (5.6), Drug Interactions (7.1), Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

3 DOSAGE FORMS AND STRENGTHS

Darifenacin Extended-Release Tablets 7.5 mg are white colored, round, biconvex filmcoated tablets debossed with L408 on one side and plain on other side.

Darifenacin Extended-Release Tablets 15 mg are light peach colored, round, biconvex film-coated tablets debossed with L409 on one side and plain on other side.

4 CONTRAINDICATIONS

Darifenacin extended-release tablets are contraindicated in patients with, or at risk for, the following conditions:

- urinary retention
- urinary relention
 asstric retention
- gastric retention, or

5 WARNINGS AND PRECAUTIONS

5.1 Risk of Urinary Retention

Darifenacin should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention.

5.2 Decreased Gastrointestinal Motility

Darifenacin should be administered with caution to patients with gastrointestinal obstructive disorders because of the risk of gastric retention. Darifenacin, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as severe constipation, ulcerative colitis, and myasthenia gravis.

5.3 Controlled Narrow-Angle Glaucoma

Darifenacin should be used with caution in patients being treated for narrow-angle glaucoma and only where the potential benefits outweigh the risks.

5.4 Angioedema

Angioedema of the face, lips, tongue, and/or larynx have been reported with darifenacin. In some cases angioedema occurred after the first dose. Angioedema associated with upper airway swelling may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, darifenacin should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided.

5.5 Central Nervous System Effects

Darifenacin is associated with anticholinergic central nervous system (CNS) effects [see Adverse Reactions (6.2)]. A variety of CNS anticholinergic effects have been reported, including headache, confusion, hallucinations and somnolence. Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose. Advise patients not to drive or operate heavy machinery until they know how darifenacin affect them. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.

5.6 Patients with Hepatic Impairment

The daily dose of darifenacin should not exceed 7.5 mg for patients with moderate hepatic impairment (Child-Pugh B). Darifenacin have not been studied in patients with severe hepatic impairment (Child-Pugh C) and therefore is not recommended for use in this patient population [see Dosage and Administration (2) Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of darifenacin was evaluated in controlled clinical trials in a total of 8,830 patients, 6,001 of whom were treated with darifenacin . Of this total, 1,069 patients participated in three, 12-week, randomized, placebo-controlled, fixed-dose efficacy and safety studies (Studies 1, 2 and 3). Of this total, 337 and 334 patients received darifenacin 7.5 mg daily and 15 mg daily, respectively. In all long-term trials combined, 1,216 and 672 patients received treatment with darifenacin for at least 24 and 52 weeks, respectively.

In Studies 1, 2 and 3 combined, the serious adverse reactions to darifenacin were urinary retention and constipation.

In Studies 1, 2 and 3 combined, dry mouth leading to study discontinuation occurred in 0 percent, 0.9 percent, and 0 percent of patients treated with darifenacin 7.5 mg daily, darifenacin 15 mg daily and placebo, respectively. Constipation leading to study discontinuation occurred in 0.6 percent, 1.2 percent, and 0.3 percent of patients treated with darifenacin 7.5 mg daily, darifenacin 15 mg daily and placebo, respectively.

Table 1 lists the rates of identified adverse reactions, derived from all reported adverse events in 2 percent or more of patients treated with 7.5 mg or 15 mg darifenacin, and greater than placebo in Studies 1, 2 and 3. In these studies, the most frequently reported adverse reactions was dry mouth and constipation. The majority of the adverse reactions were mild or moderate in severity and most occurred during the first two weeks of treatment.

Table 1: Incidence of Identified Adverse Reactions, Derived from All Adverse

Events Reported in ≥ 2 Percent of Patients Treated with Darifenacin Extended-Release Tablets Extended-Release Tablets and More Frequent with Darifenacin than with Placebo in Studies 1, 2, and 3

Body System	Adverse Reaction	Percent	age of Subj	ects
		Darifenacin	Darifenacin	Placebo
		7.5 mg	15 mg	N = 388
		N = 337	N = 334	
Digestive	Dry Mouth	20.2	35.3	8.2
	Constipation	14.8	21.3	6.2
	Dyspepsia	2.7	8.4	2.6
	Abdominal Pain	2.4	3.9	0.5
	Nausea	2.7	1.5	1.5
	Diarrhea	2.1	0.9	1.8
Urogenital	Urinary Tract Infection	4.7	4.5	2.6
Nervous	Dizziness	0.9	2.1	1.3
Body as a	Asthenia	1.5	2.7	1.3
Whole				
Eye	Dry Eyes	1.5	2.1	0.5

Other adverse reactions reported by 1 percent to 2 percent of darifenacin-treated patients include: abnormal vision, accidental injury, back pain, dry skin, flu syndrome, hypertension, vomiting, peripheral edema, weight gain, arthralgia, bronchitis, pharyngitis, rhinitis, sinusitis, rash, pruritus, urinary tract disorder and vaginitis.

Study 4 was a randomized, 12-week, placebo-controlled, dose-titration regimen study in which darifenacin was administered in accordance with dosing recommendations [see Dosage and Administration (2)]. All patients initially received placebo or darifenacin 7.5 mg daily, and after two weeks, patients and physicians were allowed to adjust upward to darifenacin 15 mg if needed. In this study, the most commonly reported adverse reactions were also constipation and dry mouth. Table 2 lists the identified adverse reactions, derived from all adverse events reported in >3 percent of patients treated with darifenacin and greater than placebo.

Table 2: Number (Percent) of Adverse Reactions, Derived from All AdverseEvents Reported in >3 Percent of Patients Treated with DarifenacinExtended-Release Tablets , and More Frequent with Darifenacin thanPlacebo, in Study 4

Adverse Reaction	Darifenacin 7.5 mg/15 mg N = 268	Placebo N = 127
Constipation	56 (20.9 percent)	10 (7.9 percent)
Dry Mouth	50 (18.7 percent)	11 (8.7 percent)
Headache	18 (6.7 percent)	7 (5.5 percent)
Dyspepsia	12 (4.5 percent)	2 (1.6 percent)
Nausea	11 (4.1 percent)	2 (1.6 percent)
Urinary Tract Infection	10 (3.7 percent)	4 (3.1 percent)
Accidental Injury	8 (3 percent)	3 (2.4 percent)
Flu Syndrome	8 (3 percent)	3 (2.4 percent)

6.2 Post Marketing Experience

The following adverse reactions have been reported during post approval use of darifenacin extended-release Tablets extended-release tablets (darifenacin). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate frequency or establish a causal relationship to drug exposure.

Dermatologic: erythema multiforme, interstitial granuloma annulare

General: hypersensitivity reactions, including angioedema with airway obstruction and anaphylactic reaction

Central Nervous: confusion, hallucinations and somnolence

Cardiovascular: palpitations and syncope

7 DRUG INTERACTIONS

7.1 CYP3A4 Inhibitors

The systemic exposure of darifenacin from Darifenacin Extended-Release Tablets

extended-release tablets is increased in the presence of CYP3A4 inhibitors. The daily dose of darifenacin should not exceed 7.5 mg when co-administered with potent CYP3A4 inhibitors (for example, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone). No dosing adjustments are recommended in the presence of moderate CYP3A4 inhibitors (for example, erythromycin, fluconazole, diltiazem and verapamil) [see Dosage and Administration (2) and Clinical Pharmacology (12.3)].

7.2 CYP2D6 Inhibitors

No dosing adjustments are recommended in the presence of CYP2D6 inhibitors (for example, paroxetine, fluoxetine, quinidine and duloxetine) [see Clinical Pharmacology (12.3)].

7.3 CYP2D6 Substrates

Caution should be taken when darifenacin is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window (for example, flecainide, thioridazine and tricyclic antidepressants) [see Clinical Pharmacology (12.3)].

7.4 CYP3A4 Substrates

Darifenacin (30 mg daily) did not have a significant impact on midazolam (7.5 mg) pharmacokinetics [see Clinical Pharmacology (12.3)].

7.5 Combination oral contraceptives

Darifenacin (10 mg three times daily) had no effect on the pharmacokinetics of the combination oral contraceptives containing levonorgestrel and ethinyl estradiol [see *Clinical Pharmacology (12.3)*].

7.6 Warfarin

Darifenacin had no significant effect on prothrombin time when a single dose of warfarin 30 mg was coadministered with darifenacin (30 mg daily) at steady-state. Standard therapeutic prothrombin time monitoring for warfarin should be continued.

7.7 Digoxin

Darifenacin (30 mg daily) did not have a clinically relevant effect on the pharmacokinetics of digoxin (0.25 mg) at steady-state. Routine therapeutic drug monitoring for digoxin should be continued [see Clinical Pharmacology (12.3)].

7.8 Other Anticholinergic Agents

The concomitant use of darifenacin with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to effects on gastrointestinal motility.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C

There are no studies of darifenacin in pregnant women.

Darifenacin was not teratogenic in rats and rabbits at plasma exposures of free drug (via AUC) up to 59 times and 28 times, respectively (doses up to 50 and 30 mg/kg/day, respectively) the maximum recommended human dose [MRHD] of 15 mg. At approximately 59 times the MRHD in rats, there was a delay in the ossification of the sacral and caudal vertebrae which was not observed at approximately 13 times the AUC. Dystocia was observed in dams at approximately 17 times the AUC (10 mg/kg/day). Slight developmental delays were observed in pups at this dose. At five times the AUC (3 mg/kg/day), there were no effects on dams or pups. In rabbits, an exposure approximately 28 times (30 mg/kg/day) the MRHD of darifenacin was shown to increase post-implantation loss, with a no effect level at nine times (10 mg/kg/day) the AUC at the MRHD. Dilated ureter and/or kidney pelvis was also observed in offspring at this dose along with urinary bladder dilation consistent with the pharmacological action of darifenacin, with one case observed at nine times (10 mg/kg/day). No effect was observed at approximately 2.8 times (3 mg/kg/day) the AUC at the MRHD.

Because animal reproduction studies are not always predictive of human response, darifenacin should be used during pregnancy only if the benefit to the mother outweighs the potential risk to the fetus.

8.3 Nursing Mothers

Darifenacin is excreted into the milk of rats. It is not known whether darifenacin is

excreted into human milk and therefore caution should be exercised before darifenacin is administered to a nursing woman.

8.4 Pediatric Use

The safety and effectiveness of darifenacin in pediatric patients have not been established.

8.5 Geriatric Use

In the fixed-dose, placebo-controlled, clinical studies, 30 percent of patients treated with darifenacin were over 65 years of age. No overall differences in safety or efficacy were observed between patients over 65 years (n = 207) and younger patients <65 years (n = 464). No dose adjustment is recommended for elderly patients [*see Clinical Pharmacology* (12.3) and Clinical Studies (14)].

8.6 Hepatic Impairment

Subjects with severe hepatic impairment (Child-Pugh C) have not been studied, therefore darifenacin is not recommended for use in these patients [see Dosage and Administration (2) and Warnings and Precautions (5.6)]. The daily dose of darifenacin should not exceed 7.5 mg once daily for patients with moderate hepatic impairment (Child-Pugh B) [see Dosage and Administration (2) and Warnings and Precautions (5.6)]. After adjusting for plasma protein binding, unbound darifenacin exposure was estimated to be 4.7-fold higher in subjects with moderate hepatic impairment than subjects with normal hepatic function. No dose adjustment is recommended for patients with mild hepatic impairment (Child-Pugh A).

8.7 Renal Impairment

A study of subjects with varying degrees of renal impairment (creatinine clearance between 10 and 136 mL/min) demonstrated no clear relationship between renal function and darifenacin clearance. No dose adjustment is recommended for patients with renal impairment [*see Clinical Pharmacology (12.3)*].

8.8 Gender

No dose adjustment is recommended based on gender [see Clinical Pharmacology (12.3) and Clinical Studies (14)].

10 OVERDOSAGE


Overdosage with antimuscarinic agents, including darifenacin, can result in severe antimuscarinic effects. Treatment should be symptomatic and supportive. In the event of overdosage, ECG monitoring is recommended. Darifenacin has been administered in clinical trials at doses up to 75 mg (five times the maximum therapeutic dose) and signs of overdose were limited to abnormal vision.

11 DESCRIPTION

Darifenacin is an extended-release tablet for oral administration which contains 7.5 mg or 15 mg darifenacin as its hydrobromide salt. The active moiety, darifenacin, is a potent muscarinic receptor antagonist.

Chemically, darifenacin hydrobromide is (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2diphenylacetamide hydrobromide. The empirical formula of darifenacin hydrobromide is $C_{28}H_{30}N_2O_2$ •HBr.

The structural formula is:



Darifenacin hydrobromide is a white to off-white crystalline powder, with a molecular weight of 507.5.

Darifenacin is a once-a-day extended-release tablet and contains the following inactive ingredients: hypromellose, povidone, dibasic calcium phosphate anhydrous, magnesium stearate, titanium dioxide, polyethylene glycol, talc. The 15 mg tablet also contains iron

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Darifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of the urinary bladder smooth muscle and stimulation of salivary secretion.

In vitro studies using human recombinant muscarinic receptor subtypes show that darifenacin has greater affinity for the M_3 receptor than for the other known muscarinic receptors (9- and 12-fold greater affinity for M_3 compared to M_1 and M_5 , respectively, and 59-fold greater affinity for M_3 compared to both M_2 and M_4). M_3 receptors are involved in contraction of human bladder and gastrointestinal smooth muscle, saliva production, and iris sphincter function. Adverse drug effects such as dry mouth, constipation and abnormal vision may be mediated through effects on M_3 receptors in these organs.

12.2 Pharmacodynamics

In three cystometric studies performed in patients with involuntary detrusor contractions, increased bladder capacity was demonstrated by an increased volume threshold for unstable contractions and diminished frequency of unstable detrusor contractions after darifenacin treatment. These findings are consistent with an antimuscarinic action on the urinary bladder.

Electrophysiology


The effect of six-day treatment of 15 mg and 75 mg darifenacin on QT/QTc interval was evaluated in a multiple-dose, double-blind, randomized, placebo- and active-controlled (moxifloxacin 400 mg) parallel-arm design study in 179 healthy adults (44 percent male, 56 percent female) aged 18 to 65. Subjects included 18 percent poor metabolizer (PMs) and 82 percent extensive metabolizer (EMs). The QT interval was measured over a 24-hour period both predosing and at steady-state. The 75 mg darifenacin dose was chosen because this achieves exposure similar to that observed in CYP2D6 poor metabolizers administered the highest recommended dose (15 mg) of darifenacin in the presence of a potent CYP3A4 inhibitor. At the doses studied, darifenacin did not result in QT/QTc interval prolongation at any time during the steady-state, while moxifloxacin treatment resulted in a mean increase from baseline QTcF of about 7 msec when compared to placebo. In this study, darifenacin 15 mg and 75 mg doses demonstrated a mean heart rate change of 3.1 and 1.3 bpm, respectively, when compared to placebo. However, in the clinical efficacy and safety studies, the change in median HR following treatment with darifenacin was no different from placebo.

12.3 Pharmacokinetics

Absorption

After oral administration of darifenacin to healthy volunteers, peak plasma concentrations of darifenacin is reached approximately seven hours after multiple dosing and steady-state plasma concentrations are achieved by the sixth day of dosing. The mean (SD) steady-state time course of darifenacin 7.5 mg and 15 mg extended-release tablets is depicted in Figure 1.

Figure 1 Mean (SD) Steady-State Darifenacin Plasma Concentration-Time Profiles for Darifenacin 7.5 mg and 15 mg in Healthy Volunteers Including Both CYP2D6 EMs and PMs*






Table 3: Mean (SD) Steady-State Pharmacokinetic Parameters from Darifenacin 7.5 mg and 15 mg Extended-Release Tablets Based on Pooled Data by Predicted CYP2D6 Phenotype

	Darife	enacin 7.5	mg (N = 6	8 EM, 5 PN	1)	Darifenacin 15 mg (N = 102 EM, 17 PM)					
	AUC ₂₄ (ng.h/ml)	C _{max} (ng/ml)	C _{avg} (ng/ml)	T _{max} (h)	T _{1/2} (h)	AUC ₂₄ (ng.h/ml)	C _{max} (ng/ml)	C _{avg} (ng/ml)	T _{max} (h)	T _{1/2} (h)	
ЕМ	29.24 (15.47)	2.01 (1.04)		6.49 (4.19)	12.43 (5.64) ^z	88.9 (67.87)	5.76 (4.24)	3.7 (2.83)	7.61 (5.06)	12.05 (12.37) ^k	
РМ	67.56 (13.13)	4.27 (0.98)	2.81 (0.55)	5.2 (1.79)	19.95 ^c -	157.71 (77.08)	9.99 (5.09)	6.58 (3.22)	6.71 (3.58)	7.4 ^{d-}	

 C_{max} = Maximum observed plasma concentration; C_{avg} = Average plasma concentration at steady-state;

 T_{max} = Time of occurrence of C_{max} ; $t_{1/2}$ = Terminal elimination half-life. Regarding EM and PM [see CLINICAL PHARMACOLOGY, Pharmacokinetics, Variability in Metabolism (12.3)].

The mean oral bioavailability of darifenacin in EMs at steady-state is estimated to be 15 percent and 19 percent for 7.5 mg and 15 mg tablets, respectively.

Effect of Food

Following single dose administration of darifenacin with food, the AUC of darifenacin was not affected, while the C_{max} was increased by 22 percent and T_{max} was shortened by 3.3 hours. There is no effect of food on multiple-dose pharmacokinetics from darifenacin.

Distribution

Darifenacin is approximately 98 percent bound to plasma proteins (primarily to alpha-1-acid-glycoprotein). The steady-state volume of distribution (Vss) is estimated to be 163 L.

Metabolism

Darifenacin is extensively metabolized by the liver following oral dosing. Metabolism is mediated by cytochrome P450 enzymes CYP2D6 and CYP3A4. The three main metabolic routes are as follows:

(i) monohydroxylation in the dihydrobenzofuran ring;(ii) dihydrobenzofuran ring opening;

(iii) N-dealkylation of the pyrrolidine nitrogen.

The initial products of the hydroxylation and N-dealkylation pathways are the major circulating metabolites but they are unlikely to contribute significantly to the overall clinical effect of darifenacin.

Variability in Metabolism

A subset of individuals (approximately 7 percent Caucasians and 2 percent African Americans) are poor metabolizers (PMs) of CYP2D6 metabolized drugs. Individuals with normal CYP2D6 activity are referred to as extensive metabolizers (EMs). The metabolism of darifenacin in PMs will be principally mediated via CYP3A4. The darifenacin ratios (PM versus EM) for C_{max} and AUC following darifenacin 15 mg once daily at steady-state were 1.9 and 1.7, respectively.

Excretion

Following administration of an oral dose of ¹⁴C-darifenacin solution to healthy volunteers, approximately 60 percent of the radioactivity was recovered in the urine and 40 percent in the feces. Only a small percentage of the excreted dose was unchanged darifenacin (3 percent). Estimated darifenacin clearance is 40 L/h for EMs and 32 L/h for PMs. The elimination half-life of darifenacin following chronic dosing is approximately 13 to 19 hours.

Drug-Drug Interactions

Effects of Other Drugs on Darifenacin

Darifenacin metabolism is primarily mediated by the cytochrome P450 enzymes CYP2D6 and CYP3A4. Therefore, inducers of CYP3A4 or inhibitors of either of these enzymes may alter darifenacin pharmacokinetics [see Drug Interactions (7)].

CYP3A4 Inhibitors: In a drug interaction study, when a 7.5 mg once daily dose of darifenacin was given to steady-state and co-administered with the potent CYP3A4 inhibitor ketoconazole 400 mg, mean darifenacin C_{max} increased to 11.2 ng/mL for EMs (n = 10) and 55.4 ng/mL for one PM subject (n = 1). Mean AUC increased to 143 and 939 ng•h/mL for EMs and for one PM subject, respectively. When a 15 mg daily dose of darifenacin was given with ketoconazole, mean darifenacin C_{max} increased to 67.6 ng/mL and 58.9 ng/mL for EMs (n = 3) and one PM subject (n = 1), respectively. Mean AUC increased to 1110 and 931 ng•h/mL for EMs and for one PM subject (n = 1), respectively. Isee Dosage and Administration (2) and Drug Interactions (7.1)].

The mean C_{max} and AUC of darifenacin following 30 mg once daily dosing at steadystate were 128 percent and 95 percent higher, respectively, in the presence of a moderate CYP3A4 inhibitor, erythromycin. Co-administration of fluconazole, a moderate CYP3A4 inhibitor and darifenacin 30 mg once daily at steady-state increased darifenacin C_{max} and AUC by 88 percent and 84 percent, respectively [see Drug Interactions (7.1)]. The mean C_{max} and AUC of darifenacin following 30 mg once daily at steady-state were 42 percent and 34 percent higher, respectively, in the presence of cimetidine, a mixed CYP P450 enzyme inhibitor.

CYP2D6 Inhibitors: Darifenacin exposure following 30 mg once daily at steady-state was 33 percent higher in the presence of the potent CYP2D6 inhibitor paroxetine 20 mg [see Drug Interactions (7.2)].

Effects of Darifenacin on Other Drugs

In Vitro Studies: Based on *in vitro* human microsomal studies, darifenacin is not expected to inhibit CYP1A2 or CYP2C9 at clinically relevant concentrations. In Vivo Studies: The potential for clinical doses of darifenacin to act as inhibitors of CYP2D6 or CYP3A4 substrates was investigated in specific drug interaction studies. CYP2D6 Substrates: The mean C_{max} and AUC of impramine, a CYP2D6 substrate, were increased by 57 percent and 70 percent, respectively, in the presence of steady-state darifenacin 30 mg once daily. The mean C_{max} and AUC of desipramine, the active metabolite of imipramine, were increased by 260 percent [see Drug Interactions (7.3)]. CYP3A4 Substrates: Darifenacin (30 mg daily) co-administered with a single oral dose of midazolam 7.5 mg resulted in a 17 percent increase in midazolam exposure.

Combination Oral Contraceptives: Darifenacin (10 mg three times daily) had no effect on the pharmacokinetics of a combination oral contraceptive containing levonorgestrel (0.15 mg) and ethinyl estradiol (0.03 mg).

Warfarin: Darifenacin had no significant effect on prothrombin time when a single

dose of warfarin 30 mg was co-administered with darifenacin (30 mg daily) at steadystate [see Drug Interactions (7.6)].

Digoxin: Darifenacin (30 mg daily) co-administered with digoxin (0.25 mg) at steadystate resulted in a 16 percent increase in digoxin exposure [see Drug Interactions (7.7)].

Pharmacokinetics in Special Populations

Age: A population pharmacokinetic analysis of patient data indicated a trend for clearance of darifenacin to decrease with age (6 percent per decade relative to a median age of 44). Following administration of darifenacin 15 mg once daily, darifenacin exposure at steady-state was approximately 12 percent to 19 percent higher in volunteers between 45 and 65 years of age compared to younger volunteers aged 18 to 44 years [see Use in Specific Populations (8.5)].

Pediatric: The pharmacokinetics of darifenacin has not been studied in the pediatric population [see Use in Specific Populations (8.4)].

Gender: PK parameters were calculated for 22 male and 25 female healthy volunteers. Darifenacin C_{max} and AUC at steady-state were approximately 57 percent to 79 percent and 61 percent to 73 percent higher in females than in males, respectively [see Use in Specific Populations (8.8)].

Renal Impairment: A study of subjects with varying degrees of renal impairment (creatinine clearance between 10 and 136 mL/min) given darifenacin 15 mg once daily to steady-state demonstrated no clear relationship between renal function and darifenacin clearance [see Use in Specific Populations (8.7)].

Hepatic Impairment: Darifenacin pharmacokinetics were investigated in subjects with mild (Child-Pugh A) or moderate (Child-Pugh B) impairment of hepatic function given darifenacin 15 mg once daily to steady-state. Mild hepatic impairment had no effect on the pharmacokinetics of darifenacin. However, protein binding of darifenacin was affected by moderate hepatic impairment. After adjusting for plasma protein binding, unbound darifenacin exposure was estimated to be 4.7-fold higher in subjects with moderate hepatic impairment than subjects with normal hepatic function. Subjects with severe hepatic impairment (Child-Pugh C) have not been studied [see Dosage and Administration (2), Warning and Precautions (5.5) and Use in Specific Population (8.6)].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity studies with darifenacin were conducted in mice and rats. No evidence of drug-related carcinogenicity was revealed in a 24-month study in mice at dietary doses up to 100 mg/kg/day or approximately 32 times the estimated free plasma AUC reached at the maximum recommended human dose (the AUC at the MRHD) of 15 mg and in a 24-month study in rats at doses up to 15 mg/kg/day or up to approximately 12 times the AUC at the MRHD in female rats and approximately eight times the AUC at the MRHD in male rats.

Darifenacin was not genotoxic in the bacterial mutation assay (Ames test), the Chinese hamster ovary assay, the human lymphocyte assay, or the *in vivo* mouse bone marrow cytogenetics assay.

There was no evidence for effects on fertility in male or female rats treated at oral doses up to approximately 78 times (50 mg/kg/day) the AUC at the MRHD.

14 CLINICAL STUDIES

Darifenacin extended-release tablets extended-release tablets were evaluated for the treatment of patients with overactive bladder with symptoms of urgency, urge urinary incontinence, and increased urinary frequency in three randomized, fixed-dose, placebo-controlled, multicenter, double-blind, 12-week studies (Studies 1, 2 and 3) and one randomized, double-blind, placebo-controlled, multicenter, dose-titration study (Study 4). For study eligibility in all four studies, patients with symptoms of overactive bladder for at least six months were required to demonstrate at least eight micturitions and at least one episode of urinary urgency per day, and at least five episodes of urge urinary incontinence per week. The majority of patients were white (94 percent) and female (84 percent), with a mean age of 58 years, range 19 to 93 years. Thirty-three percent of patients were \geq 65 years of age. These characteristics were well balanced across treatment groups. The study population was inclusive of both naïve patients who had not received prior pharmacotherapy for overactive bladder (60 percent) and those who had (40 percent).

Table 4 shows the efficacy data collected from 7- or 14-day voiding diaries in the three fixed-dose placebo-controlled studies of 1,059 patients treated with placebo, 7.5 mg or 15 mg once daily darifenacin for 12 weeks. A significant decrease in the primary endpoint, change from baseline in average weekly urge urinary incontinence episodes was observed in all three studies. Data is also shown for two secondary endpoints, change from baseline in the average number of micturitions per day (urinary frequency) and change from baseline in the average volume voided per micturition.

Table 4: Difference Between Darifenacin (7.5 mg, 15 mg) and Placebo for the Week 12 Change from Baseline (Studies 1, 2 and 3)

		Study 1			Study 2		Study 3		
	Darifenacin	Darifenacin	Placebo		Darifenacin	Placebo	Darifenaci	nPlacebo	
	7.5 mg	15 mg		7.5 mg	15 mg		15 mg		
No. of	229	115	164	108	107	109	112	115	
Patients									
Entered									
Urge Inco	ntinence Ep	oisodes per	Week						
Median	16.3	17	16.6	14	17.3	16.1	16.2	15.5	
Baseline									
Median	-9	-10.4	-7.6	-8.1	-10.4	-5.9	-11.4	-9	
Change									
from									
Baseline									
Median	-1.5*	-2.1*	-	-2.8*	-4.3*	-	-2.4*	-	
Difference				_					
to Placebo									
Micturitio	ns per Day	1 1		1	1 1		1		
Median	10.1	10.1	10.1	10.3	11	10.1	10.5	10.4	
Baseline									
Median	-1.6	-1.7	-0.8	-1.7	-1.9	-1.1	-1.9	-1.2	
Change									
from									
Baseline									
Median	-0.8*	-0.9*	-	-0.5	-0.7*	-	-0.5	-	
Difference									
to Placebo									
Volume of	f Urine Pass	sed per Void	l (mL)					1	
Median	160.2	151.8	162.4	161.7	157.3	162.2	155	147.1	
Baseline									
Median	14.9	30.9	7.6	16.8	23.6	7.1	26.7	4.6	
Change									
from									
Baseline									
Median	9.1*	20.7*	-	9.2	16.6*	-	20.1*	-	
Difference	-			-			-		
to Placebo									

*Indicates statistically significant difference versus placebo (p<0.05, Wilcoxon rank-sum test)

Table 5 shows the efficacy data from the dose-titration study in 395 patients who initially received 7.5 mg darifenacin or placebo daily with the option to increase to 15 mg darifenacin or placebo daily after two weeks.

Table 5: Difference between Darifenacin (7.5 mg/15 mg) and Placebo for the Week 12 Change from Baseline (Study 4)

	Darifenacin	Placebo
	7.5 mg/15 mg	
No. of Patients Treated	268	127
Urge Incontinence Episodes per	Week	
Median Baseline	16	14
Median Change from Baseline	-8.2	-6
Median Difference to Placebo	-1.4*	-
Micturitions per Day		
Median Baseline	9.9	10.4
Median Change from Baseline	-1.9	-1
Median Difference to Placebo	-0.8*	-
Volume of Urine Passed per Void	l (mL)	
Median Baseline	173.7	177.2
Median Change from Baseline	18.8	6.6
Median Difference to Placebo	13.3*	-

*Indicates statistically significant difference versus placebo (p<0.05, Wilcoxon rank-sum test)

As seen in Figures 2 a, b and c, reductions in the number of urge incontinence episodes per week were observed within the first two weeks in patients treated with darifenacin 7.5 mg and 15 mg once daily compared to placebo. Further, these effects were sustained throughout the 12-week treatment period.

Figures 2a, 2b, 2c. Median Change from Baseline at Weeks 2, 6, 12 for Number of Urge Incontinence Episodes per Week (Studies 1, 2 and 3)




Figure 2b, Study 2





Figure 2c, Study 3



16 HOW SUPPLIED/STORAGE AND HANDLING

Darifenacin Extended-Release Tablets 7.5 mg are white colored, round, biconvex filmcoated tablets debossed with L408 on one side and plain on other side. Bottle of 30

Bottle of 90 Bottle of 1000 NDC 46708-223-90

NDC46708-223-91

80 (10 x 8) Tablets Unit Dose Blister Pack NDC46708-223-08

Darifenacin Extended-Release Tablets 15 mg are light Peach colored, round, biconvex film-coated tablets debossed with L409 on one side and plain on other side.

Chavana	
80 (10 x 8) Tablets Unit Dose Blister Pack	NDC46708-224-08
Bottle of 1000	NDC46708-224-91
Bottle of 90	NDC46708-224-90
Bottle of 30	NDC 46708-224-30

Storage

Store at 25° C (77° F); excursions permitted to 15 to 30° C (59 to 86° F) [see USP Controlled Room Temperature]. Protect from light.

Keep this and all drugs out of the reach of children.

17 PATIENT COUNSELING INFORMATION

"See FDA-approved patient labeling (Patient Information)"

Patients should be informed that anticholinergic agents, such as darifenacin, may produce clinically significant adverse effects related to anticholinergic pharmacological activity including constipation, urinary retention and blurred vision. Heat prostration (due to decreased sweating) can occur when anticholinergics such as darifenacin are used in a hot environment. Because anticholinergics, such as darifenacin, may produce dizziness or blurred vision, patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until the drug's effects have been determined. Patients should read the patient information leaflet before starting therapy with darifenacin.

Patients should be informed that darifenacin may produce clinically significant angioedema that may result in airway obstruction. Patients should be advised to promptly discontinue darifenacin therapy and seek immediate medical attention if they experience edema of the tongue or laryngopharynx, or difficulty breathing.

Darifenacin extended-release tablets should be taken once daily with water. They may be taken with or without food, and should be swallowed whole and not chewed, divided or crushed.

FDA-Approved Patient Labeling

Darifenacin (dar-i-FEN-a-sin)

Extended-Release Tablets

Read this Patient Information leaflet about darifenacin before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or your treatment.

What is darifenacin ?

Darifenacin is prescription medicine for adults used to treat the following symptoms due to a condition called overactive bladder:

- Urge urinary incontinence: a strong need to urinate with leaking or wetting accidents
- Urgency: a strong need to urinate right away
- Frequency: urinating often
- It is unknown if darifenacin is safe and effective in children.

Who should not take darifenacin?

Do not take darifenacin if you:

- are not able to empty your bladder ("urinary retention")
- have delayed or slow emptying of your stomach ("gastric retention")
- have an eye problem called "uncontrolled narrow-angle glaucoma"

What should I tell my healthcare provider before starting darifenacin? Before starting darifenacin, tell your doctor if you:

- have trouble emptying your bladder or if you have a weak urine stream
- · have any stomach or intestinal problems, or problems with constipation
- have liver problems
- have any other medical conditions
- are pregnant or are planning to become pregnant. It is not known if darifenacin can harm your unborn baby.

• are breastfeeding or plan to breastfeed. It is not known if darifenacin passes into breast milk and if it can harm your baby. Talk to your doctor about the best way to feed your baby if you take

darifenacin.

Tell your healthcare provider about all the medicines you take, including

prescription and nonprescription medicines, vitamins, and herbal supplements. Darifenacin and certain other medicines may affect each other, causing side effects.

Especially tell your healthcare provider if you take a: • antifungal medicine ketoconazole (Nizoral[®]) or itraconazole (Sporanox[®])

- antibiotic medicine clarithromycin (Biaxin[®])
- anti-HIV medicine ritonavir (Norvir[®]) or nelfinavir (Viracept[®])
- medicine to treat depression nefazadone (Serzone[®])
- medicine to treat an abnormal heartbeat flecainide (Tambocor®)
- antipsychotic medicine thioridazine (Mellaril[®])
- medicine to treat depression called a tricyclic antidepressant

Know all the medicines you take. Keep a list of them with you to show your doctor and pharmacist each time you get a new medicine.

How should I take darifenacin?

• Take darifenacin exactly as prescribed. Your doctor will prescribe the dose that is right

for you. Take darifenacin 1 time daily with water.

- Darifenacin should be swallowed whole. Do not chew, cut or crush darifenacin.
- Darifenacin may be taken with or without food.

• If you take too much darifenacin call your doctor or go to the nearest hospital emergency room right away.

What should I avoid while taking darifenacin?

Darifenacin can cause blurred vision or dizziness. Do not drive or operate heavy machinery until you know how darifenacin affect you.

What are the possible side effects of darifenacin?

Darifenacin may cause serious side effects including: • Serious allergic reaction. Stop taking darifenacin and get medical help right away if

you have:

o hives, skin rash or swelling

o severe itching

o swelling of your face, mouth or tongue

o trouble breathing

The most common side effects with darifenacin is:

- constipation
- dry mouth
- headache
- heartburn
- nausea
- urinary tract infection
- blurred vision

• heat exhaustion or heat-stroke. This can happen when darifenacin is used in hot

environments. Symptoms of heat exhaustion may include:

o decreased sweating

- o dizziness
- o tiredness
- o nausea

o increase body temperature

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of darifenacin. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How do I store darifenacin?

• Store darifenacin at room temperature, between 59°F to 86°F (15°C to 30°C).

• Keep darifenacin out of the light.

Keep darifenacin and all medicines out of the reach of children.

General information about darifenacin.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use darifenacin for a condition for which it was not prescribed. Do not give darifenacin to other people, even if they have the same symptoms you have. It may harm them.

This Patient Information leaflet summarizes the most important information about darifenacin. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about darifenacin that is written for health professionals.

What are the ingredients in darifenacin extended-release tablets? Active ingredient: darifenacin

Inactive ingredients: hypromellose, povidone, dibasic calcium phosphate anhydrous, magnesium stearate, titanium dioxide, polyethylene glycol, talc. The 15 mg tablet also contains iron oxide red and iron oxide yellow.

The brands listed are the trademarks of their respective owners and are not trademarks of Alembic Pharmaceuticals Limited.

Manufactured by: Alembic Pharmaceuticals Limited (Formulation Division), Village Panelav, P. O. Tajpura, Near Baska, Taluka-Halol, Panchmahal, Gujarat, India.

Revised: 04/2016

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL -7.5 mg

Darifenacin Extended-Release Tablets 7.5 mg (30 Tablets in 1 HDPE Bottle) Each tablet contains 8.929 mg of darifenacin hydrobromide to provide 7.5 mg darifenacin. 46708-223-30



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL -15 mg

Darifenacin Extended-Release Tablets 15 mg (30 Tablets in 1 HDPE Bottle) Each tablet contains 17.858 mg of darifenacin hydrobromide to provide 15 mg darifenacin. 46708-224-30

Each tablet contains 17.858 mg of darferacin hydrobromide to provide 15 mg darifenacin. Usual Dosage: One tablet daily. Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature].	NDC 46708-224-30 Darifenacin Extended-Releas Tablets 15 mg	ed by: ed by: nomecenticals Limited n Division), a Disparat, India. G959 G959 G959 C959 C959 C959 C959 C959	12/2017
Protect from light.	Rx only 30 Table	c. No. c. No.	
Keep this and all drugs out of the reach of children.	Alembic	Manuf Alemb Kerme Migage Migage Migage Migage Migage Migage Migage Migage Migage Migage Migage Migage Migage Migage Migage Migage Manuf Alemb Al	EXP:

DARIFENACIN					
darifenacin tablet, extended	release				
Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	ltem Code	(Source)	NDC:4	5708-223
Route of Administration	ORAL				
Active Ingredient/Active	e Moiety				
In	gredient Name		Basis o Streng		Strength
DARIFENACIN HYDROBROMIDE UNII:APG9819VLM)	(UNII: CR02EYQ8GV) (DARIFENACIN	-	DARIFENACIN		7.5 mg
Inactive Ingredients					
	Ingredient Name			St	rength

PO AN	HYDROUS DIBA							
MA	GNESIUM STE	ARATE (UNII: 70	097M6I30)					
	ANIUM DIOXID							
	LYETHYLENE G LC (UNII: 75EV7)		JNII: 1212Z7S33A)					
		41(10)						
Pr	oduct Char	acteristics						
Co	lor	WHITE (Whit		Scor	e			no score
Shape ROUND (BICONVEX)				Size				3mm
	ivor ntains			Impr	int Code		L	_408
CU	intains							
Pa	ackaging							
ŧ	ltem Code	Pa	ckage Description	I	Marketin Dat		Ma	rketing En Date
	NDC:46708- 223-30	30 in 1 BOTTLE Product	; Type 0: Not a Combination	12	/12/2017	-		
,	NDC:46708- 223-90		; Type 0: Not a Combination	12	/12/2017			
2	NDC:46708-	1000 in 1 BOT	TLE; Type 0: Not a Combination	12	/12/2017			
4	223-91 NDC:46708-		R PACK; Type 0: Not a Combinatio	-	/12/2017			
	223-08	Product						
Μ	arketing							
	Marketing Category	Applica	tion Number or Monograph Citation		Marketir Da		Ma	arketing En Date
AN		ANDA20768	1	1	2/12/2017			
aı	ARIFENAC	t, extended n	elease					
lai Pi	ifenacin table roduct Infor	t, extended n		lta	om Code i	(Source)	N	IDC:46708-224
laı Pı Pr	ifenacin table roduct Infor oduct Type	t, extended n r mation	HUMAN PRESCRIPTION DRUG	lte	em Code ((Source)	N	IDC:46708-224
laı Pı Pr	ifenacin table roduct Infor	t, extended n r mation		lte	em Code ((Source)	N	IDC:46708-224
laı Pı Pr	ifenacin table roduct Infor oduct Type	t, extended n r mation	HUMAN PRESCRIPTION DRUG	lte	em Code I	(Source)	N	IDC:46708-224
laı Pı Rc	ifenacin table roduct Infor oduct Type	t, extended r rmation istration	HUMAN PRESCRIPTION DRUG ORAL	lte	em Code (IDC:46708-224
laı Pı Rc	ifenacin table roduct Infor oduct Type oute of Admin	t, extended r rmation istration ient/Active	HUMAN PRESCRIPTION DRUG ORAL	lte	em Code	Basi	is of	Streng
lai Pi Pr Rc Ac	ifenacin table roduct Infor oduct Type oute of Admin :tive Ingred	t, extended r rmation istration ient/Active Ing	HUMAN PRESCRIPTION DRUG ORAL Moiety		em Code e	Basi Stre	is of ngth	Streng
lai Pi Pr Rc Ac	ifenacin table roduct Infor oduct Type pute of Admin ctive Ingred	t, extended r rmation istration ient/Active Ing	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name		em Code I	Basi	is of ngth	Streng
lai Pi Rc Ac	ifenacin table roduct Infor oduct Type oute of Admin :tive Ingred	t, extended r rmation istration ient/Active Ing	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name		em Code I	Basi Stre	is of ngth	Streng
Pr Rc	ifenacin table roduct Infor oduct Type oute of Admin :tive Ingred	t, extended r rmation istration ient/Active Ing DROBROMIDE (HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name		em Code e	Basi Stre	is of ngth	Streng
Pr Rc	ifenacin table roduct Infor oduct Type oute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM)	t, extended r rmation istration ient/Active Ing DROBROMIDE (HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name		em Code i	Basi Stre	is of ngth	Streng
Pr Rc Ac	ifenacin table roduct Infor oduct Type oute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingre PROMELLOSE,	t, extended r rmation istration ient/Active Ing DROBROMIDE (edients UNSPECIFIED	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN Ingredient Name (UNII: 3NXW29V3WO)		em Code e	Basi Stre	is of ngth	Streng
Pr Rc Ac	ifenacin table roduct Infor oduct Type pute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingre PROMELLOSE, VIDONE K30 (L	t, extended n rmation istration ient/Active Ing DROBROMIDE (edients UNSPECIFIED JNII: U725QW32	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN Ingredient Name (UNII: 3NXW29V3WO) :X)		em Code i	Basi Stre	is of ngth	Streng
AC DA UN In HY PO	ifenacin table roduct Infor oduct Type pute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingre PROMELLOSE, VIDONE K30 (L	t, extended n rmation istration ient/Active ing pROBROMIDE (edients UNSPECIFIED JNII: U725QWY32 ASIC CALCIUM	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN Ingredient Name (UNII: 3NXW29V3WO) X) PHOSPHATE (UNII: L11K75P92J)		em Code i	Basi Stre	is of ngth	Streng
AC DA UN In HY PO AN	ifenacin table roduct Infor oduct Type pute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingre PROMELLOSE, VIDONE K30 (U HYDROUS DIBA	t, extended n mation istration ient/Active ing DROBROMIDE (edients UNSPECIFIED JNII: U725QWY32 ASIC CALCIUM ARATE (UNII: 70	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN Ingredient Name (UNII: 3NXW29V3WO) XX) PHOSPHATE (UNII: L11K75P92J) 097M6130)		em Code I	Basi Stre	is of ngth	Streng
Ac Ac DA JN In HY PO AN	ifenacin table roduct Infor oduct Type pute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingre PROMELLOSE, VIDONE K30 (L HYDROUS DIBA GRESIUM STEA CANIUM DIOXID LYETHYLENE G	t, extended n mation istration ient/Active ing DROBROMIDE (edients UNSPECIFIED JNII: U725QWY32 ASIC CALCIUM ARATE (UNII: 70 E (UNII: 15FIX9V GLYCOL 1500 (I	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN Ingredient Name (UNII: 3NXW29V3WO) XX) PHOSPHATE (UNII: L11K75P92J) 097M6130)		em Code I	Basi Stre	is of ngth	Streng
AC AC AC AC AC AC AC AC AC AC AC AC AC A	ifenacin table roduct Infor oduct Type oute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingre PROMELLOSE, VIDONE K30 (U HYDROUS DIBA GRESIUM STEA TANIUM DIOXID LYETHYLENE G LC (UNII: 75EV7)	t, extended r rmation istration ient/Active ing DROBROMIDE (edients UNSPECIFIED JNII: U725QW32 SIC CALCIUM ARATE (UNII: 70 E (UNII: 15FIX9V SILYCOL 1500 ((4R1U)	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN (UNII: 3NXW29V3WO) (2) PHOSPHATE (UNII: L11K75P92J) 097M6130) (2)P) JNII: 1212Z7533A)		em Code i	Basi Stre	is of ngth	Streng
AC DA JN IN HY PO TA FE	ifenacin table roduct Infor oduct Type pute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingre PROMELLOSE, VIDONE K30 (L HYDROUS DIBA GRESIUM STEA CANIUM DIOXID LYETHYLENE G	t, extended r rmation istration ient/Active ing DROBROMIDE (edients UNSPECIFIED JNII: U725QWY32 ASIC CALCIUM ARATE (UNII: 70 E (UNII: 15FIX9V SLYCOL 1500 (I 14R1U) LLOW (UNII: EX	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN (UNII: 3NXW29V3WO) (UNII: 3NXW29V3WO) (UNII: 11K75P92J) 097M6I30) 2JP) JNII: 1212Z7533A) 43802MRT)		em Code i	Basi Stre	is of ngth	Streng
AC DA JN IN HY PO TA FE	ifenacin table roduct Infor oduct Type sute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingre PROMELLOSE, VIDONE K30 (L HYDROUS DIBA GNESIUM STEA ANIUM DIOXID LYETHYLENE G LC (UNII: 75EV7] RRIC OXIDE YE	t, extended r rmation istration ient/Active ing DROBROMIDE (edients UNSPECIFIED JNII: U725QWY32 ASIC CALCIUM ARATE (UNII: 70 E (UNII: 15FIX9V SLYCOL 1500 (I 14R1U) LLOW (UNII: EX	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN (UNII: 3NXW29V3WO) (UNII: 3NXW29V3WO) (UNII: 11K75P92J) 097M6I30) 2JP) JNII: 1212Z7533A) 43802MRT)		em Code i	Basi Stre	is of ngth	Streng
lai Pr Rc Ac DAA DAA DAA N M HY PO OAN M FE FE	ifenacin table roduct Infor oduct Type sute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingre PROMELLOSE, VIDONE K30 (L HYDROUS DIBA GNESIUM STEA ANIUM DIOXID LYETHYLENE G LC (UNII: 75EV7] RRIC OXIDE YE	t, extended n mation istration ient/Active ing DROBROMIDE (edients UNSPECIFIED JNII: U725QWY32 ASIC CALCIUM RRATE (UNII: 70 ie (UNII: 15FiX9V SLYCOL 1500 ((4R1U) LLOW (UNII: EX. D (UNII: 1K09F34	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN (UNII: 3NXW29V3WO) (UNII: 3NXW29V3WO) (UNII: 11K75P92J) 097M6I30) 2JP) JNII: 1212Z7533A) 43802MRT)		em Code i	Basi Stre	is of ngth	Streng
Iar Pr Rc DAAC DAAN HY PO OAN MAAN MAAN FE FE FE	ifenacin table roduct Infor oduct Type pute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingred PROMELLOSE, VIDONE K30 (L HYDROUS DIBA GANESIUM STEA CANIUM DIOXID CANIUM DIOXID CANIUM DIOXID CANIUM DIOXID CANIUM DIOXID CANIUM DIOXID CANIUM DIOXID CANIUM CONDE YE RRIC OXIDE YE RRIC OXIDE RE	t, extended n mation istration ient/Active ing DROBROMIDE (edients UNSPECIFIED JUNI: U725QWY32 ASIC CALCIUM ARATE (UNII: 70 E (UNII: 15FIX94 SUYCOL 1500 ((44R1U) LLOW (UNII: EX. D (UNII: 1K09F3(acteristics	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN (UNII: 3NXW29V3WO) (UNII: 3NXW29V3WO) (UNII: 11K75P92J) 097M6I30) 2JP) JNII: 1212Z7533A) 43802MRT)		em Code e	Basi Stre	is of ngth	Streng
lar Pr Pr Rc DAAC DAAC DAAC DAAC DAAC DAAC DAAC DAA	ifenacin table roduct Infor oduct Type pute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingred PROMELLOSE, VIDONE K30 (L HYDROUS DIA GNESIUM STEA - ANIUM DIOXID LYETHYLENE G LC (UNII: 75EV7) RRIC OXIDE YE RRIC OXIDE RE	t, extended n mation istration ient/Active ing DROBROMIDE (edients UNSPECIFIED JUNI: U725QWY32 ASIC CALCIUM ARATE (UNII: 70 E (UNII: 15FIX94 SUYCOL 1500 ((44R1U) LLOW (UNII: EX. D (UNII: 1K09F3(acteristics	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN (UNII: 3NXW29V3WO) (X) PHOSPHATE (UNII: L11K75P92)) 097M6130) (2)P) JNII: 1212Z7533A) 43802MRT) 5675)			Basi Stre	is of ngth	Strength
Ian Pr Pr Rc DAA DAA In HY PO AN MAA FE FE Pr FE FE	ifenacin table roduct Infor oduct Type pute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingred PROMELLOSE, VIDONE K30 (L HYDROUS DIBA GNESIUM STEA CANIUM DIOXID LYETHYLENE G LC (UNII: 7SEV7) RRIC OXIDE YE RRIC OXIDE YE RRIC OXIDE RE roduct Char- lor ape	t, extended n mation istration ient/Active ing DROBROMIDE (edients UNSPECIFIED JNII: U725QWY32 ASIC CALCIM CALCINII: 170 E (UNII: 170 E (UNII: 15FIX94 SUYCOL 1500 (1 44R1U) LLOW (UNII: EX. D (UNII: 1K09F34 acteristics ORANGE (Light	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN (UNII: 3NXW29V3WO) (X) PHOSPHATE (UNII: L11K75P92)) 097M6130) (2)P) JNII: 1212Z7533A) 43802MRT) 5675)		Score	Basi Stre DARIFENAC	is of ngth	no score
dar Pr Rc DAAC DAAC DAAC DAAC DAAC DAAC DAAC DAA	ifenacin table roduct Infor oduct Type pute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingred PROMELLOSE, VIDONE K30 (L HYDROUS DIBA GANESIUM STEA CANIUM DIOXID CANIUM DIOXIUM DIOXID CANIUM DIOXID CANIUM DIOXID CANIUM DIOXID	t, extended n mation istration ient/Active ing DROBROMIDE (edients UNSPECIFIED JNII: U725QWY32 ASIC CALCIM CALCINII: 170 E (UNII: 170 E (UNII: 15FIX94 SLYCOL 1500 (1 44R1U) LLOW (UNII: EX. D (UNII: 1K09F34 acteristics ORANGE (Light	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN (UNII: 3NXW29V3WO) (X) PHOSPHATE (UNII: L11K75P92)) 097M6130) (2)P) JNII: 1212Z7533A) 43802MRT) 5675)		Score	Basi Stre DARIFENAC	is of ngth	No score 8mm
lar Pr Rc DAA DAA DAA DAA DAA DAA DAA TIN PO TAA FEE Pr TA FEE Pr Coo	ifenacin table roduct Infor oduct Type pute of Admin :tive Ingred RIFENACIN HYI active Ingred PROMELLOSE, VIDONE K30 (U HYDROUS DIBA GNESIUM STEA GNESIUM STEA CANIUM DIOXID LYETHYLENE G LC (UNII: 75EV7) RRIC OXIDE YE RRIC OXIDE YE RRIC OXIDE RE roduct Char- lor ape avor ntains	t, extended n mation istration ient/Active ing DROBROMIDE (edients UNSPECIFIED JNII: U725QWY32 ASIC CALCIM CALCINII: 170 E (UNII: 170 E (UNII: 15FIX94 SLYCOL 1500 (1 44R1U) LLOW (UNII: EX. D (UNII: 1K09F34 acteristics ORANGE (Light	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN (UNII: 3NXW29V3WO) (X) PHOSPHATE (UNII: L11K75P92)) 097M6130) (2)P) JNII: 1212Z7533A) 43802MRT) 5675)		Score	Basi Stre DARIFENAC	is of ngth	No score 8mm
lan Pri Rac DAA DAA DAA DAA DAA DAA DAA DAA DAA DA	ifenacin table roduct Infor oduct Type pute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingred PROMELLOSE, VIDONE K30 (L HYDROUS DIA GNESIUM STEA - ANIUM DIOXID LYETHYLENE G LC (UNII: 75EV7) RRIC OXIDE YE RRIC OXIDE RE roduct Char- lor ape Nor ntains	t, extended n mation istration ient/Active ing DROBROMIDE (edients UNSPECIFIED JUNI: U725QW32 ASIC CALCIUM ARATE (UNII: 170 E (UNII: 151599 SUYCOL 1500 ((44R1U) LLOW (UNII: EX. D (UNII: 1K09F3) acteristics ORANGE (Light ROUND (BICOM	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN (UNII: 3NXV29V3WO) (UNII: 3NXV29V3WO) (UNII: 3NXV29V3WO) (UNII: 1212Z7533A) 43802MRT) G675) FPeach Colored) (VEX)		Score	Basi	is of ngth :IN	No score 8mm
lan Pr Rc DAAC DAAC DAAC DAAC DAAC DAAC DAAC DAA	ifenacin table roduct Infor oduct Type pute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingred PROMELLOSE, VIDONE K30 (U HYDROUS DIBA GONESIUM STEA CANIUM DIOXID LYETHYLENE G LC (UNII: 7SEV7) RRIC OXIDE YE RRIC OXIDE RE roduct Char- lor ape ivor ntains	t, extended r rmation istration ient/Active ing DROBROMIDE (edients UNSPECIFIED UNI: U725QWY32 ASIC CALCIUM ARATE (UNII: 70 E (UNII: 100 SLYCOL 1500 (I 4R1U) LLOW (UNII: EX D (UNII: 1K09F3) acteristics ORANGE (Light ROUND (BICON	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN Ingredient Name (UNII: 3NXW29V3WO) (UNII: 3NXW29V3WO) (UNII: 3NXW29V3WO) (UNII: 3NXW29V3WO) (UNII: 1212Z7533A) PHOSPHATE (UNII: L11K75P92J) 097M6130) (2)P) SOPO PHOSPHATE (UNII: L11K75P92J) 097M6130) (2)P) SOPO PHOSPHATE (UNII: L11K75P92J) 097M6130) (2)P) SOPO PHOSPHATE (UNII: L11K75P92J) (2)P) SOPO PHOSPHATE (UNII: L11K75P92J) (2)P) SOPO (2)P) SOPO (2)P) (2)P) (2)P) (2)P) (2)P) (2)P) (2)P) (2)P) (2)P) (2)P) (3)P) (3)P) (4)P) (Score Size Imprint (Marketin Dat	Basi Stre DARIFENAC	is of ngth :IN	No Streng 15 mg I5 mg Strength I No Strength Ino Strength
lar Pr Rc DAAC DAAC DAAC DAAC DAAC DAAC DAAC DAA	ifenacin table roduct Infor oduct Type pute of Admin :tive Ingred RIFENACIN HYI II:APG9819VLM) active Ingred PROMELLOSE, VIDONE K30 (L HYDROUS DIA GNESIUM STEA - ANIUM DIOXID LYETHYLENE G LC (UNII: 75EV7) RRIC OXIDE YE RRIC OXIDE RE roduct Char- lor ape Nor ntains	t, extended n mation istration istration ient/Active ing DROBROMIDE (edients UNSPECIFIED JNII: U725QWY32 ASIC CALCIUM ARATE (UNII: 70 ie (UNII: 15FI394 SLYCOL 1500 ((4R1U) LLOW (UNII: EX. D (UNII: 1K09F34 ACTERISTICS ORANGE (Light ROUND (BICON BOUND	HUMAN PRESCRIPTION DRUG ORAL Moiety redient Name UNII: CR02EYQ8GV) (DARIFENACIN (UNII: 3NXV29V3WO) (UNII: 3NXV29V3WO) (UNII: 3NXV29V3WO) (UNII: 1212Z7533A) 43802MRT) G675) FPeach Colored) (VEX)		Score Size Imprint (Basi Stre DARIFENAC	is of ngth :IN	Strength 15 mg Strength Strength L409

Ma	Marketing Category	INTORMATION Application Number or Monograph Citation	Marketing Start Date	Marketing End Date			
Ma	arketing	Information					
Marketing Information							
	IDC:46708- 24-08	08 in 1 BLISTER PACK; Type 0: Not a Combination Product	12/12/2017				
2	IDC:46708- 24-91	1000 in 1 BOTTLE; Type 0: Not a Combination Product	12/12/2017				

Labeler - Alembic Pharmaceuticals Limited (650574663)

Establishment			
Name	Address	ID/FEI	Business Operations
Alembic Pharmaceuticals Limited		650574671	MANUFACTURE(46708-223, 46708-224)

Revised: 1/2023

Alembic Pharmaceuticals Limited